Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
| Published in: | Journal of Clinical Oncology Vol. 41; pp. 9572 - 9573 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2023 Supplement 16
|
| Online Access: | View this record in EBSCOhost |
| Description not available. |